Drugs in the pipeline

Share this content:

Cardiovascular

Amlodipine besylate + olmesartan medoxomil (from Daiichi Sankyo) calcium channel blocker plus angiotensin receptor blocker combination being reviewed for the treatment of hypertension — NDA submitted

Rivaroxaban (from Bayer and Ortho-McNeil) an oral Factor Xa inhibitor being studied for stroke prevention in atrial fibrillation and treatment and long-term secondary prevention of venous thromboembolism —Phase 3

Editor’s note: Brand names and all other information are subject to change before the product launches.

You must be a registered member of Clinical Advisor to post a comment.

Sign Up for Free e-newsletters